Signatera is a personalized, tumor-informed ctDNA assay for molecular residual disease (MRD) detection and treatment response monitoring in patients previously diagnosed with cancer. Signatera is optimized to detect low levels of ctDNA, to help stratify high risk patients and optimize patient management. Discover more at: www.natera.com/oncology/signatera-advanced-cancer-detection/
Additional Info
- Banner Image URL: images/Sponsor/Natera_Signatera_Logo.jpg
- Website URL: https://www.natera.com
Published in
Silver Sponsors
Latest from Dave Venus
Leave a comment
Make sure you enter all the required information, indicated by an asterisk (*). HTML code is not allowed.
